Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 19Skin Neoplasms 6Lung Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Melanoma 5Colorectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma 4Neoplasms 3Mouth Neoplasms 3Colonic Neoplasms 3Breast Neoplasms 3Adenocarcinoma 3Recurrence 2Ovarian Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Basal Cell 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Solid Tumors 1

Interventions

Cyclophosphamide 25fludarabine 19Dexamethasone 17pembrolizumab 13Rituximab 12venetoclax 9Lenalidomide 9Gemcitabine 9Etoposide 9pomalidomide 8Vincristine 7glofitamab 6fludarabine phosphate 6carfilzomib 6Temozolomide 6obinutuzumab 5daratumumab 5Prednisone 5Nivolumab 5Doxorubicin 5Cisplatin 5Calcium Dobesilate 5Bortezomib 5zanubrutinib 4selinexor 4Immunotherapy, Adoptive 4Cytarabine 4Carboplatin 4Azacitidine 4ruxolitinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × cemiplimab × 90 days × Clear all
NCT06769698 2026-05-06

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Regeneron Pharmaceuticals

Phase 2 Recruiting
120 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT07567469 2026-05-05

A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma

Regeneron Pharmaceuticals

Phase 1/2 Not yet recruiting
120 enrolled
CNS

Ependymoma, Glioma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡